

2013

1. Tzankov A, Xu-Monette ZY, Gerhard M, Visco C, Dirnhofer S, Gisin N, Dybkaer K, Orazi A, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Ponzoni M, Ferreri AJ, Ye Q, Winter JN, Farnen JP, Piris MA, Møller MB, You MJ, McDonnell T, Medeiros LJ, Young KH. Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. *Mod Pathol*. 2013 Dec 13. doi: 10.1038/modpathol.2013.214. [Epub ahead of print] PubMed [PMID: 24336156](#).
2. Bøgsted M, Bilgrau AE, Wardell CP, Bertsch U, Schmitz A, Bødker JS, Kjeldsen MK, Goldschmidt H, Morgan GJ, Dybkaer K, Johnsen HE. Proof of the concept to use a malignant B cell line drug screen strategy for identification and weight of melphalan resistance genes in multiple myeloma. *PLoS One*. 2013 Dec 20;8(12):e83252. doi: 10.1371/journal.pone.0083252. PubMed [PMID: 24376673](#).
3. Mylam KJ, El-Galaly TC, Hutchings M, Brown P, Himmelstrup B, Gerke O, Gillstrøm D, Sillesen IB, Munksgaard L, Pedersen BB, Christiansen I, Jensen P, Nielsen AL, Pedersen LM. Prognostic impact of clinician-based interpretation of 18F-fluorodeoxyglucose positron emission tomography/computed tomography reports obtained in patients with newly diagnosed diffuse large B-cell lymphoma. *Leuk Lymphoma*. 2014 Jul;55(7):1563-9. doi: 10.3109/10428194.2013.850165. Epub 2013 Nov 14. PubMed [PMID: 24144339](#).
4. Murphy BL, Obad S, Bihannic L, Ayrault O, Zindy F, Kauppinen S, Roussel MF. Silencing of the miR-17~92 Cluster Family Inhibits Medulloblastoma Progression. *Cancer Res*. 2013 Dec 1;73(23):7068-78. doi: 10.1158/0008-5472.CAN-13-0927. Epub 2013 Oct 21. PubMed [PMID: 24145352](#); PubMed Central PMCID: PMC3857104.
5. Rottiers V, Obad S, Petri A, McGarrah R, Lindholm MW, Black JC, Sinha S, Goody RJ, Lawrence MS, Delemos AS, Hansen HF, Whittaker S, Henry S, Brookes R, Najafi-Shoushtari SH, Chung RT, Whetstone JR, Gerszten RE, Kauppinen S, Näär AM. Pharmacological Inhibition of a MicroRNA Family in Nonhuman Primates by a Seed-Targeting 8-Mer AntimiR. *Sci Transl Med*. 2013 Nov 20;5(212):212ra162. doi: 10.1126/scitranslmed.3006840. PubMed [PMID: 24259050](#).
6. Lanza F, Campioni DC, Hellmann A, Milone G, Wahlin A, Walewski J, Spedini P, Fiamenghi C, Cuneo A, Knopińska W, Swierkowska-Czeneszew M, Petriz J, Fruehauf S, Farge D, Mohty M, Passweg J, Ruutu T, Madrigal A, Johnsen HE; Individual Quality Assessment of Haematopoietic Stem Cell Grafting Committee of European Blood and Marrow Transplantation Society. Individual Quality Assessment of Autografting by Probability Estimation for Clinical Endpoints: A Prospective Validation Study from the European Group for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. 2013 Aug 27. doi:pii: S1083-8791(13)00382-0. 10.1016/j.bbmt.2013.08.005. [Epub ahead of print] PubMed [PMID: 23988403](#).
7. Blijlevens N, de Château M, Krivan G, Rabitsch W, Szomor A, Pytlik R, Lissmats A, Johnsen HE, de Witte T, Einsele H, Ruutu T, Niederwieser D; CLWP of the EBMT. In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral mucositis or related patient's burden. *Bone Marrow Transplant*. 2013 Jul;48(7):966-71. doi: 10.1038/bmt.2012.257. Epub 2012 Dec 17. PubMed [PMID: 23241739](#).
8. Xu-Monette ZY, Møller MB, Tzankov A, Montes-Moreno S, Hu W, Manyam GC, Fan L, Visco C, Dybkaer K, Chiu A, Tam W, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huang Q, Huh J, Ai W, Ponzoni M, Ferreri AJ, Winter JN, Wu L, Zhao X, Go RS, Wang SA, Bueso-Ramos CE, Li Y, Piris MA, Medeiros LJ, Young KH. MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy. *Blood*. 2013 Aug 27. [Epub ahead of print] PubMed [PMID: 23982177](#).
9. Johnsen HE, Bergkvist KS, Schmitz A, Kjeldsen MK, Hansen SM, Gaihede M, Nørgaard MA, Bæch J, Grønholdt ML, Jensen FS, Johansen P, Bødker JS, Bøgsted M, Dybkaer K; for the Myeloma Stem Cell Network (Mscnet). Cell of origin associated classification of B-cell malignancies by gene signatures of the normal B-cell hierarchy. *Leuk Lymphoma*. 2013 Nov 1. [Epub ahead of print] PubMed [PMID: 23998255](#).
10. Ammitzbøll CG, Steffensen R, Nielsen HJ, Thiel S, Stengaard-Pedersen K, Bøgsted M, Jensenius JC (2013) Polymorphisms in the MASP1 Gene are Associated with Serum Levels of MASP-1, MASP-3, and MASP4. *PLoS ONE* 8(9): e73317. doi:10.1371/journal.pone.0073317. See publication [here](#)
11. Dabrowska MJ, Ejegod D, Lassen LB, Johnsen HE, Wabl M, Pedersen FS, Dybkaer K. Gene expression profiling of murine T-cell lymphoblastic lymphoma identifies deregulation of S-phase initiating genes.

12. Frei E, Visco C, Xu-Monette ZY, Dirnhofer S, Dybkær K, Orazi A, Bhagat G, Hsi ED, van Krieken JH, Ponzoni M, Go RS, Piris MA, Møller MB, Young KH, Tzankov A. Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma. *J Clin Pathol*. 2013 Jun 17. [Epub ahead of print] PubMed [PMID: 23775435](#).
13. Liu C, Iqbal J, Teruya-Feldstein J, Shen Y, Dabrowska MJ, Dybkaer K, Lim MS, Piva R, Barreca A, Pellegrino E, Spaccarotella E, Lachel CM, Kucuk C, Jiang CS, Hu X, Bhagvati S, Greiner TC, Weisenburger DD, Aoun P, Perkins SL, McKeithan TW, Inghirami G, Chan WC. MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma. *Blood*. 2013 Jun 25. [Epub ahead of print] PubMed [PMID: 23801630](#).
14. Lassen LB, Füchtbauer A, Schmitz A, Sørensen AB, Pedersen FS, Füchtbauer EM. Septin9 is involved in T-cell development and CD8(+) T-cell homeostasis. *Cell Tissue Res*. 2013 May 4. [Epub ahead of print] PubMed [PMID: 23644740](#).
15. Rodrigo-Domingo M, Waagepetersen R, Bødker JS, Falgreen S, Kjeldsen MK, Johnsen HE, Dybkær K, Bøgsted M. Reproducible probe-level analysis of the Affymetrix Exon 1.0 ST array with R/Bioconductor. *Brief Bioinform*. 2013 Apr 19. [Epub ahead of print] PubMed [PMID: 23603090](#).
16. Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, van der Meer AJ, Patack AK, Chen A, Zhou Y, Persson R, King BD, Kauppinen S, Levin AA, Hodges MR. Treatment of HCV infection by targeting microRNA. *N Engl J Med*. 2013 May 2;368(18):1685-94. doi: 10.1056/NEJMoa1209026. Epub 2013 Mar 27. PubMed [PMID: 23534542](#).
17. Li Y, Gordon MW, Xu-Monette ZY, Visco C, Tzankov A, Zou D, Qiu L, Montes-Moreno S, Dybkaer K, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huang Q, Ai W, Ponzoni M, Ferreri AJ, Winter JN, Go RS, Piris MA, Møller MB, Wu L, Wang M, Ramos KS, Medeiros LJ, Young KH. Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program. *Blood*. 2013 Mar 20. [Epub ahead of print] PubMed [PMID: 23515929](#).
18. Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, Balasubramanyam A, Liu WM, Visco C, Li Y, Miranda RN, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Zhao X, van Krieken JH, Huang Q, Huh J, Ai W, Ponzoni M, Ferreri AJ, Zhou F, Slack GW, Gascoyne RD, Tu M, Variakojis D, Chen W, Go RS, Piris MA, Møller MB, Medeiros LJ, Young KH. MYC/BCL2 protein co-expression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program Study. *Blood*. 2013 Feb 28. [Epub ahead of print] PubMed [PMID: 23449635](#).
19. Pettengell R, Johnsen HE, Lugtenburg PJ, Silvestre AS, Dührsen U, Rossi FG, Schwenkglenks M, Bendall K, Szabo Z, Jaeger U. Erratum to: Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma. *Support Care Cancer*. 2013 Feb;21(2):653. doi: 10.1007/s00520-012-1678-2. PubMed [PMID: 23224655](#).
20. Hu S, Xu-Monette ZY, Balasubramanyam A, Manyam GC, Visco C, Tzankov A, Liu WM, Miranda RN, Zhang L, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huang Q, Huh J, Ai W, Ponzoni M, Ferreri AJ, Zhao X, Winter JN, Zhang M, Li L, Møller MB, Piris MA, Li Y, Go RS, Wu L, Medeiros LJ, Young KH. CD30 expression defines a novel subset of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from The International DLBCL Rituximab-CHOP Consortium Program Study. *Blood*. 2013 Jan 23. [Epub ahead of print] PubMed [PMID: 23343832](#).
21. 2013 El-Galaly TC. Rutine knoglemarvsundersøgelser ændrer sjældent behandlingen af Hodgkin lymfom, *Best Practice* 2013 (August, nr. 7), ISSN 1903-6582

CLINICAL INVESTIGATOR IN INTERNATIONAL CLINICAL TRIALS NOW PUBLISHED

1. Alan K. Burnett, Nigel H. Russell, Robert K. Hills, Ann E. Hunter, Lars Kjeldsen, John Yin, Brenda E.S. Gibson, Keith Wheatley, and Donald Milligan. Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial. *J Clin Oncol*. 2013 August 12. [Epub ahead of print]